Clinical Trial

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by \> 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-22.
Status change: Not Yet Recruiting → Recruiting 2024-04-01
Trial Details
NCT Number NCT05514015
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Conditions Primary Membranous Nephropathy
Enrollment 78 participants
Start Date 2024-03-29
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-02